one starts the process, the other boosts it
Searches were performed in PubMed, ScienceDirect, and Google Scholar for publications between 1 January 2000 and 31 March 2025, using Boolean operators to combine terms such as (GLP-1 receptor agonist OR GLP-1 RA OR semaglutide OR liraglutide OR dulaglutide OR exenatide OR tirzepatide) AND (smoking cessation OR nicotine dependence OR nicotine addiction OR tobacco use disorder), as well as (GLP-1 receptor agonist OR GLP-1 RA) AND (weight gain OR obesity OR weight management OR post-cessation weight gain)
Decades of research show it is safe, naturally occurring, and capable of supporting the body in remarkable ways, from skin health to cellular repair to stress resilience
As per the GLP-1 receptor agonist market overview, trulicity accounts for the largest share of the global market largely due to its reliable effectiveness, well-established and clinically verified safety credentials, and ease of once-a-week dosing